Skip to main content
Equibles
CELC logo

CELC · Celcuity Inc.

Track CELC — free

Use CELC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CELC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$90.57 -3.08 (-3.29%) At close · Aug 20
Market Cap
$4.43B
Shares
48.93M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$90.57 Open$92.90 Day$90.26–93.36 52W close$45.22–144.98 Avg vol 30d1.4M Short int10.3M · 21.0% float · 6.8d Short vol68% Last earningsAug 13, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Oct 13, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −14%
      below
      Price vs 50-day avg −3%
      below
      RSI (14) 48
      neutral
      MACD trend Positive
      52-week position 45%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +3%
      trailing
      6-month return −19%
      trailing
      YTD return −9%
      this year
      Relative strength −30%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $94 › 200d $105 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +60 funds added
      Insider flow Distributing
      Net -$317.8M over 90 days · 100% sells
      Short interest Falling
      20.97% of float · ▼ -8.0% MoM · 6.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      278 holders — near 3-yr high, broad support
      Squeeze score 64
      elevated · 0–100
      Fundamentals
      Weak
      EPS growth −34%
      Y/Y
      Free cash flow $-153.5M
      Balance sheet $28.2M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 77%
      annualized · 1-yr
      Max drawdown −43%
      past year
      ATR 5.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 5 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −14% Bearish
      Price vs 50-day avg
      −3% Neutral
      RSI (14)
      48 Neutral
      MACD trend
      Positive Bullish
      52-week position
      45% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $94 › 200d $105 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +60 funds added
      Insider flow Distributing
      Net -$317.8M over 90 days · 100% sells
      Short interest Falling
      20.97% of float · ▼ -8.0% MoM · 6.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      278 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $45 Now $91 · 45% Range high $145
      vs 200-day avg -14% vs 50-day avg -3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP GAAP net loss -$78.86M
      +$2.24M Stock-based compensation - Research and development
      +$4.66M Stock-based compensation - Selling, general and administrative
      +$1.47M Non-cash interest expense
      +$332K Non-cash investment (income) expense
      +$11.48M Loss on debt extinguishment
      = Non-GAAP adjusted net loss -$58.68M
      Non-GAAP adjusted net loss per share non-GAAP $1.07 the second quarter of 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP net loss per share - basic and diluted -$1.44
      +$0.04 Stock-based compensation - Research and development
      +$0.08 Stock-based compensation - Selling, general and administrative
      +$0.03 Non-cash interest expense
      +$0.01 Non-cash investment (income) expense
      +$0.21 Loss on debt extinguishment
      = Non-GAAP adjusted net loss per share - basic and diluted -$1.07

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CELC
      Celcuity Inc.
      this stock
      		$4.43B -9.2% — — 21.0%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      278
      % held
      119.5%
      Net QoQ
      +7.1M sh
      Top holder
      BAKER BROS. ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      240
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      10.3M
      Days to cover
      6.8d
      Change
      -889.3K sh
      View
      Short Volume
      Short vol %
      68%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      48.4K
      Value
      $4.0M
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      49.0%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$317.8M
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Tom Malinowski
      Amount
      $1.0K–$15.0K
      Traded
      May 26, 2021
      View
      Financials
      Financials
      Net income (FY)
      $-177.0M
      EPS diluted
      $-3.79
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Sep 30, 2026
      This year
      20
      View
      Proposed Sales
      Value
      $291.0M
      Shares
      2.8M
      Filed
      Jul 14, 2026
      View
      Exempt Offerings
      Offering
      $352.7M
      Filed
      Sep 23, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CELC +4.6% +2.5% -18.9% +4.9% -9.2%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +6.5% -0.8% -30.1% +2.8% -21.0%
      Key facts CIK 1603454 CUSIP 15102K100 13F (30d) 265 filings 262 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)